GenMark Diagnostics

GenMark Diagnostics is a molecular diagnostics company focused on developing and commercializing its sensor detection technology. The Company’s electrochemical technology enables the detection of up to 72 distinct biomarkers in a single sample. Its XT-8 System has received 510(k) clearance from the United States Food and Drug Administration (FDA) and is designed to support a range of molecular diagnostic tests with a compact workstation and self-contained, disposable test cartridges. Within 30 minutes of receipt of an amplified deoxyribonucleic acid (DNA) sample, its XT-8 System produces results. The XT-8 System supports up to 24 test cartridges, which can be run independently, and are targeted for hospitals and reference laboratories. The Company is also developing its next-generation platform, the AD-8 System, to integrate DNA amplification with its sensor detection technology to enable technicians to place a minimally prepared patient sample into its test cartridge.

Adaptive Biotechnologies

Barnwell Industries

Roche Holding AG

Meridian Bioscience

Meridian Bioscience Inc. (NASDAQ:VIVO) edged out GenMark Diagnostics Inc. (NASDAQ:GNMK) as the top gainer in the March GenomeWeb Index with a 25% boost in its share price compared to GenMark's 22.5% increase. At the other end of the spectrum were Adaptive Biotechnologies Corp. (NASDAQ:ADPT), whose shares plummeted 28%, Burning Rock Biotech (BRN) with a 25% decline and Quanterix Corp. (QNTX), which fell 22.8%.

GenomeWeb Index Drops 3% for 2nd Consecutive Month

Cadence Bank

Luminex

Nuance Communications

NEW YORK, April 13, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Luminex Corporation (NASDAQ: LMNX)  concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to DiaSorin S.p.A. for $37.00 per share.

INVESTIGATION ALERT: Halper Sadeh LLP Investigates LMNX, NUAN, CADE, GNMK; Shareholders are Encouraged to Contact the Firm

GenMark Diagnostics (GNMK) has moved higher as of late, but there could definitely be trouble on the horizon for this company

GenMark Diagnostics (GNMK) Enters Overbought Territory

NEW YORK, March 19, 2021 /PRNewswire/ --  Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating  GenMark Diagnostics, Inc. ("GNMK" or "the Company") ( GNMK ) relating to its proposed acquisition by Roche Holdings, Inc. Under the terms of the agreement, GNMK shareholders will receive $24.05 per share in cash. The investigation focuses on whether GenMark Diagnostics, Inc. and its Board of Directors violated securities laws and/or breached their fiduciary duties to the Company by 1) failing to conduct a fair process, and 2) whether the transaction is properly valued.

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of GenMark Diagnostics, Inc. - GNMK

NEW YORK and SAN DIEGO, March 16, 2021 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating GenMark Diagnostics ("GenMark") (NASDAQ: GNMK) regarding possible breaches of fiduciary duties and other violations of law related to GenMark's agreement  to be acquired by F. Hoffman La-Roche Ltd.

GENMARK DIAGNOSTICS INVESTIGATION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP is investigating the GenMark Diagnostics acquisition by F. Hoffman La-Roche Ltd.

GenMark Diagnostics (GNMK) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

GenMark Diagnostics (GNMK) Soars 29.6%: Is Further Upside Left in the Stock?

A healthcare titan is acquiring the diagnostic-test maker for a hefty premium.

Why GenMark Stock Soared Today

WILMINGTON, Del., March 15, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating GenMark Diagnostics, Inc. (“GenMark”) (NASDAQ GM: GNMK) regarding possible breaches of fiduciary duties and other violations of law related to GenMark's agreement to be acquired by Roche Holdings, Inc. Under the terms of the agreement, GenMark's shareholders will receive $24.05 in cash per share.

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of GenMark Diagnostics, Inc. Buyout

GenMark Diagnostics Inc (NASDAQ:GNMK) stock is surging today, up 29.1% to trade at $23.88 at last check, after news of its buyout.

GNMK Grabs Fresh Highs on Billion-Dollar Buyout Buzz

NEW YORK, March 15, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of GenMark Diagnostics, Inc. ("GenMark" or the "Company") (NASDAQ: GNMK) in connection with the proposed acquisition of the Company by Roche Holdings, Inc., a global pioneer in pharmaceuticals and diagnostics. The transaction is structured as an all-cash tender offer in which the Company's shareholders will receive $24.05 for each share of GenMark that they hold.

SHAREHOLDER ALERT: WeissLaw LLP Investigates GenMark Diagnostics, Inc.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of GenMark Diagnostics, Inc. (NASDAQ: GNMK) to Roche is fair to GenMark shareholders. Under the terms of the merger agreement, Roche will acquire all outstanding shares of GenMark common stock for $24.05 per share in cash. Halper Sadeh encourages GenMark shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 7

GenMark Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of GenMark Diagnostics, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – GNMK

Shares of U.S.-based GenMark were shooting higher on Monday, after Swiss pharmaceutical group Roche said it will buy the California-based company.

GenMark Shares Surge After Roche Announces $1.8 Billion Deal for Molecular Test Maker

Roche (RHHBY) signs an agreement to acquire GenMark Diagnostics to test a broad range of pathogens using one patient sample. The deal is valued at around $1.8 billion on a fully diluted basis.

Roche (RHHBY) Inks Deal to Acquire GenMark Diagnostics for $1.8B

The stock price of GenMark Diagnostics, Inc (NASDAQ: GNMK) is trading at over 25% pre-market. This is why it happened.

GNMK Stock Price Increases Over 25% Pre-Market: Why It Happened

Roche Holding AG (SWX: RO) said on Monday that it will buy GenMark Diagnostics (NASDAQ: GNMK) for £1.29 billion. The all-cash deal translates to £17.25 per share.

Roche to buy U.S. based GenMark Diagnostics for £1.29 billion

Swiss drug giant Roche Holding AG (OTC: RHHBY) announced a big-ticket acquisition that would boost its presence in the diagnostics market, setting the tempo for a merger Monday. What Happened: Roche said it has entered into a definitive agreement to acquire GenMark Diagnostics (NASDAQ: GNMK) for $24.05 per share in cash, or about $1.8 billion, on a fully diluted basis.

Roche Boosts Diagnostics Portfolio With $1.8B Bet On COVID-19 Test Manufacturer GenMark

Roche will buy GenMark Diagnostics, a U.S.-based maker of molecular diagnostic tests in a $1.8 billion deal, the Swiss pharmaceuticals manufacturer said on Monday.

Roche agrees to buy GenMark Diagnostics in $1.8 billion deal

GenMark Diagnostics, Inc. (GNMK) CEO Scott Mendel on Q4 2020 Results - Earnings Call Transcript

CARLSBAD, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that its ePlex Respiratory Pathogen Panel 2 (RP2) is predicted to detect known SARS-CoV-2 variants currently in circulation.

GenMark ePlex® RP2 Panel Predicted to Detect Known SARS-CoV-2 Variants Currently in Circulation Based on in silico Analysis

GenMark Diagnostics (GNMK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GenMark Diagnostics (GNMK) Expected to Beat Earnings Estimates: Should You Buy?

CARLSBAD, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) (“GenMark” or the “Company”), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in the upcoming Cowen 41st Annual Health Care Conference.

GenMark Diagnostics to Participate in the Cowen 41st Annual Health Care Conference

Major teaching hospital in Grenoble, France demonstrates that ePlex BCID results could have modified antimicrobial treatment in 45% of patients Major teaching hospital in Grenoble, France demonstrates that ePlex BCID results could have modified antimicrobial treatment in 45% of patients

Study Highlights Potential Clinical Value of ePlex® Blood Culture ID Panels

CARLSBAD, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) today announced that it plans to release its fourth quarter and full year earnings results after market close on Thursday, February 25, 2021. Management will hold a conference call to review the company's financial performance starting at 4:30 p.m. ET on the same day. The conference call will be concurrently webcast.

GenMark Diagnostics to Report Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021

Bloomberg stated that GenMark Diagnostics Inc (NASDAQ: GNMK) is reportedly exploring a sale and has been contacted by multiple potential buyers. The company is said to have engaged a financial advisor to help it navigate acquisition discussions.

GenMark Surges On Report Of Potential Takeover Amid Interest From Buyers: Bloomberg

The company could be a potential acquisition target.

News for GenMark Diagnostics Stock (GNMK)